Presentation on theme: "Andrea M Girman, MD, MPH VOMA 27 April 2012"— Presentation transcript:
1 Andrea M Girman, MD, MPH VOMA 27 April 2012 The Continuum of PreD: Guiding Diagnosis & Treatment of Progression to DiabetesAndrea M Girman, MD, MPHVOMA27 April 2012
2 that constitute the subject of this presentation: NA/Non-Clinical The Continuum of PreD: Guiding Diagnosis & Treatment of Progression to DiabetesAndrea M. Girman, MD, MPH The following potential conflict of interest relationships are germane to my presentation: Equipment: None Speakers Bureau: None Stock Shareholder: None Grant/Research Support: None Consultant: NoneEmployment: Genova Diagnostics Status of FDA devices used for the material being presented: NA/Non-Clinical Status of off-label use of devices, drugs or other materialsthat constitute the subject of this presentation: NA/Non-Clinical
3 Continuum of PreD: Conversation Goals Examine the focus on obesity as major identifier of people at risk for Type 2 DMIdentify an underlying driver of progression to Type 2 Diabetes: InflammationDefine the Stages of Pre-Diabetes progressionConsider Stage-specific Therapeutic Interventions ~ Lifestyle +/- Meds
4 Challenging Assumptions Obesity:Challenging AssumptionsMany clinicians assume that they can accurately predict patient risk for diabetes based on obesity.If this is true, are tests designed to assess risk of diabetes really needed?
6 Overweight/Obesity Worldwide % Population (2007) New Zealand62.6%United Kingdom61.0%Iceland60.2%Luxembourg54.8%Ireland51%Finland48.9%Canada46.8%Slovak Republic46.2%Italy45.5%NetherlandsSweden44.0%Switzerland37.3%Notes:1. Source: Organisation for Economic Co-operation and Development (OECD) Health Data Frequently Requested Data2.Overweight is defined as a BMI between 25 and 30 kg/m² (25≤ BMI <30 kg/m²) which is same as the HSE.3.Obesity is defined as a BMI of 30 kg/m² or more (BMI ≥30 kg/m²).4. Data for Luxembourg, New Zealand, Slovak Republic and the United Kingdom are based on actual height and weight measurements rather than self-reported data.
7 Obesity Trends* Among U.S. Adults BRFSS, 1990, 2000, 2010 No Data <10% %–14% %–19% %–24% %–29% ≥30%
8 Rates of CardioMetabolic Syndrome BMI < 25BMI 25-30BMI >30MEN30%51%71%WOMEN21%43%65%TOTAL26%46%68%Rates of CardioMetabolic Syndrome
9 CDC: Only 40% of the risk of developing diabetes occurs in people who are obese. How do we find the 60% of people at risk for developing diabetes who are NOT obese?
10 PreD Assessment & Clinical Utility Identify patients who are at risk for diabetes & who are not obeseDefine that individual’s stage of progression to Type 2 Diabetes (i.e. Insulin Resistance/Cardio-Metabolic Syndrome)Provide stage-specific therapeutic interventions.
11 The Significance of Type 2 Diabetes Mellitus According to the CDC, 10% of the US population has diabetes today.By the year 2050, the CDC projects that % will be diagnosed with diabetes.This will lead to a 2-4x increase in health care costs, or approximately $171 billion per year.
12 Elementary:In order to live, cells need to burn fuel for energy & the preferred fuel is glucose.Insulin from the pancreas binds to cell receptor sites -> allows glucose to enter the cell & be used for energy.Inflammation can lead to insulin resistance-> glucose levels increase in the blood.Cells still need fuel -> fats are broken down and mobilized through lipolysis.
13 Type 2 DM Pathophysiology Initial compensation of IR by increased pancreatic β-cell insulin secretionLifestyle considerations leading to IRInsulin drives differentiation of mesenchymal stem cells into pre-adipocytes and adipose tissueConcomitant qualitative β-cell dysfunction as cellular cleavage capacity of proinsulinto insulin exhaustedAdded adipogenic effect of proinsulinPfutzner A, et al A Biomarker Concept for Assessment of Insulin Resistance , β-Cell Function and Chronic Systemic Inflammation in Type 2 Diabetes Mellitus. Clin Lab 2008; 54:
14 Type 2 DM Pathophysiology Increased hormonal secretion & increased caloric intake = increased production of visceral adipose tissueVisceral adipose tissue is metabolically activeCytokines (adipokines) which negatively influence IRSupression of adiponectin secretion by mature adipose tissue = increased visceral adipose production, increased IR, decreased vasoprotective and anti-atherosclerotic effects
15 Pfutzner A, et al A Biomarker Concept for Assessment of Insulin Resistance , β-Cell Function and Chronic Systemic Inflammation in Type 2 Diabetes Mellitus. Clin Lab 2008; 54:
25 Inflammation: A Critical Underlying Driver Inflammation is a major driver of the progression to diabetes through each stage.“Inflammation causes insulin resistance . . .” – Jerrald M. Olefsky, MDThe use of multiple inflammatory markers provides greater insight into the effects of inflammation -> one marker for inflammation may not provide a full clinical picture.OlefskyFaculty of the Division of Endocrinology & Metabolism UCSDAssociate Dean for Scientific Affairs and Professor of Medicine‘Clinical investigation approaches include studies aimed at identifying in vivo mechanisms underlying the pathogenesis of non-insulin dependent diabetes mellitus, obesity, and other disorders of insulin resistance.’
26 Markers of Inflammation hs-CRPAcute phase response protein/IRInterleukin IL-6Inflammatory cytokine/abdominal obesityInterleukin IL-8Tumor Necrosis Factor Alpha (TNFα)Plasminogen Activator Inhibitor 1 (PAI-1)Acute phase response protein/visceral obesitySurvey of peer-reviewed literature = most well-validated for relationship of risk to Type 2 DM
35 Adiponectin Protective adipose-derived protein Plays an important role in regulating glucose and lipid metabolismModerates fat tissuePromotes insulin sensitivityIs inversely related to glucose & insulinDecreases hepatic glucose & lipid productionProtects against atherosclerosis by suppressing vascular inflammation (anti-inflammatory)(refer to my notes on Drid S article)
36 Low Adiponectin associated with: Insulin resistanceGlucose intoleranceDyslipidemiaIncreased risk of vascular injury & atherosclerosisIncreased risk of diabetes mellitusInflammation(refer to my notes on Drid S article)
37 Stage 1: Early Insulin Resistance Pattern recognition:LOW Adiponectin‘Normal’ Glucose, HbA1C, Insulin, and ProinsulinNormal or slightly high HOMA-IRTreat with diet, lifestyle, supplementation.“Normal” fasting blood sugar = < 100 mg/dLBlood sugar >87 mg/dL = progressive increase of type 2 DM.Blood sugar < 81 mg/dL = low risk of DMNEJM 2005;353:
38 Stage 1 – Early Insulin Resistance Stage 1 of metabolic dysglycemia represents early insulin resistance, with adequate pancreatic beta cell compensation to maintain normal glucose. Insulin level may be normal or high. Adiponectin, which provides protection against insulin resistance, diabetes and cardiovascular disease, is typically low. Dyslipidemia may or may not be present, including elevated triglycerides and LDL-C, and/or low HDL-C.At this stage, dietary and lifestyle measures are usually adequate for improving insulin sensitivity and preventing progression to Stage 2.Treatment recommendations for Stage 1:Medication considerationsLifestyle considerationsDietary considerationsSupplement considerationsMinimize sugar and refined carbohydrates, fructose, soft drinks, and saturated fats. Avoid trans fats.Emphasize a low-saturated fat, Mediterranean-type diet (complex carbohydrates, fresh fruits and vegetables, nuts & other monounsaturates, foods rich in omega-3 fats, such as cold water fish).Nutritional: B vitamins, vitamin D, biotin, magnesium, zinc, chromium, alpha-lipoic acid & other antioxidants, fish oils;Herbal: Green tea, cinnamon, fenugreek;Hormonal: DHEA (if low)Reduce excess weight;Increase physical activity;Reduce stress ;Treat inflammatory disorders (TNF-α inhibits adiponectin)Meds are not usually needed at this stage if dietary and lifestyle measures are followed.
40 Stage 2: Elevated Fasting Insulin Pattern recognition:LOW AdiponectinHIGH or high-normal HOMA-IRHIGH Insulin, but normal ProinsulinMildly elevated glucose and/or HbA1CFasting glucose mg/dl and/or 2-hr pp glucose mg/dl and/or HbA1C %Usually due to a combination of insulin resistance & early beta-cell impairment24 million cases of type 2 DM in the U.S., but 57 million cases of ‘pre-diabetes’Treat with diet, lifestyle, supplementation, possible pharmacotherapy.(Cases of DM and prediabetes): Garber AJ ‘08/ : “Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.”– article available for $12.
41 Stage 2 – Elevated Fasting Insulin Treat any inflammatory disorders Stage 2 represents impaired glucose tolerance, usually due to combination of insulin resistance and early pancreatic beta-cell impairment. In most cases of insulin resistance, compensatory increased insulin secretion is sufficient to prevent hyperglycemia. However, in combination with beta-cell dysfunction, hyperglycemia can develop.1Adiponectin is usually low, and glucose and/or HbA1C are elevated, although not yet to a diabetic level. Insulin is usually elevated. Dyslipidemia may or may not be present, including elevated triglycerides and LDL-C, and/or low HDL-C.At this stage, diet and lifestyle measures, along with supplementation can help improve insulin sensitivity, restore proper glucose regulation, and prevent progression to diabetes (Stage 3).Treatment recommendations for Stage 2Supplement considerationsLifestyle considerationsDietary considerationsMedication considerationsAvoid sugar and refined carbohydrates, fructose, soft drinks, alcohol, and trans fats. Minimize saturated fats.Emphasize a high-fiber, low-saturated fat, Mediterranean-type diet (e.g., legumes and whole grains, fresh fruits and vegetables, nuts & other monounsaturates, foods rich in omega-3 fats, such as cold water fish).Nutritional: B vitamins, vitamin D, biotin, Mg, Zn, Cr, α-lipoic acid & other antioxidants, flavonoids (e.g., grape seed extract), fish oils, fiber supplement;Herbal: Gymnema sylvestre, green tea, cinnamon, fenugreek;Hormonal: DHEA (if low)Insulin sensitizers: Biguanides (e.g., metformin); Dual PPAR agonists (e.g., aleglitazar); Inhibitors of starch digestion: α-Glucosidase inhibitors (e.g., acarbose);Improvement of HbA1C: DPP-4 Inhibitors (e.g., sitagliptin) or PramlintideReduce weight;Increase physical activity (esp. aerobic);Reduce stress;Treat any inflammatory disorders
43 Proinsulin Produced by pancreatic β-cells Precursor to insulin Serves as a marker of later stage β-cell dysfunction & insulin resistanceHas been used in trials (proinsulin/insulin ratio) to describe improved β-cell function resulting from β-cell sensitizing meds (ie, biguanides/Metformin, TZDs/Actose)
44 Proinsulinβ-cell dysfunction impaired cleavage of proinsulin to insulin levels of proinsulin increaseHigher circulating levels of circulating proinsulin (compared to insulin) indicate advancing β-cell dysfunction & increased risk or presence of diabetes.With advancing pre-diabetes, levels of both insulin & proinsulin decline.
45 Stage 3: Elevated Proinsulin Pattern recognition:LOW AdiponectinHIGH Insulin & Elevated ProinsulinHIGH HOMA-IRHIGH Glucose & HbA1CMay or may not meet ADA definition for Type 2 Diabetes MellitusFasting Glucose > 125 mg/dLHgbA1c > 6.5%Treat with diet, lifestyle, supplementation, and pharmacotherapy.
46 Stage 3 – Elevated Pro-Insulin Treat any inflammatory disorders Stage 3 represents the development of diabetes, with insulin resistance and progressive pancreatic beta-cell impairment. Beta-cell dysfunction can result from glucose toxicity, inflammatory cytokines, oxidative stress, and/or lipotoxicity in the presence of excess glucose.1,2Glucose and HbA1C are significantly elevated, and insulin may or may not be elevated, depending on beta-cell capacity to produce adequate insulin. Sequential measurements can help reveal the degree of beta-cell dysfunction; declining insulin along with increasing proinsulin signifies late-stage impairment. The most important therapeutic goal at this stage is to normalize and maintain normal blood glucose levels.3At this stage, a comprehensive approach is essential, including diet and lifestyle measures, supplementation, and targeted pharmaceuticals, based on the degree of beta-cell impairment.Treatment recommendations for Stage 3Lifestyle considerationsDietary considerationsSupplement considerationsMedication considerationsAvoid sugar and refined carbohydrates, fructose, soft drinks, alcohol, and trans fats. Minimize saturated fats.Emphasize a high-fiber, low-saturated fat, Mediterranean-type diet (e.g., legumes and whole grains, fresh fruits and veggies, nuts & other monounsaturates, foods rich in omega-3 fats, such as cold water fish).Nutritional: B vitamins (esp. niacinamide, B6, B12, folate), vitamin D, biotin, Mg, Zn, Cr, V, antioxidants (e.g., NAC, vitamins C, E, α-lipoic acid, Se), flavonoids (e.g., grape seed, bilberry), fish oils, fiber supplement, carnosine;Herbal: Gymnema, green tea, cinnamon, fenugreek, maitake, American or Panax ginseng, rehmannia, scutellariaInsulin sensitizers: Thiazolidinediones (e.g., pioglitazone); Biguanides (e.g., metformin); Dual PPAR agonists (e.g., aleglitazar); Inhibitors of starch digestion: α-Glucosidase inhibitors (e.g., acarbose); Improvement of HbA1C: DPP-4 Inhibitors (e.g., sitagliptin) or Pramlintide; AGE Inhibitor: Aminoguanidine; Insulin secretagogues: Sulfonylureas (e.g., glipizide); Meglitinides; exanatide; Insulin & K channel openersReduce weight;Increase physical activity (esp. aerobic);Reduce stress;Treat any inflammatory disorders
49 Hemoglobin A1c (HbA1c)Measures the amount of hemoglobin in a red blood cell (RBC) that has been glycated by excess glucose.Reflects average glucose concentration during the previous 3 month period ~ the life cycle of the RBC.
50 HOMA-IR Homeostatic Model Assessment- Insulin Resistance Calculation based on plasma levels of:Fasting Glucose & InsulinNon-invasive, mathematical estimate insulin resistanceThis model correlated well with estimates using the euglycemic clamp method (r = 0.88).The authors have tested HOMA extensively against other measures of insulin resistance (or its reciprocal, insulin sensitivity) and β-cell function.HOMA-IR = FBG x insulin/405
51 C-PeptideC-peptide is produced when proinsulin is cleaved to form insulin and C-peptide.Increased levels of C-peptide reflect insulin resistance.
53 Leptin Leptin is an adipocyte-derived hormone that regulates appetite. In a healthy body, overeating induces leptin production which suppresses appetite and controls weight gain.Leptin is protective against obesity.
58 Key Points on Progression to Diabetes Can be preventedCan be reversedCan be treated effectivelyMetabolic processes may be present when the patient is not yet symptomatic.
59 Obesity: Final Considerations Obesity remains a major clinical concern. Insulin resistance is a major cause of obesity (at least 70%).Diabetes Prevention Program trial showed 58% reduction in incidence of T2DM with lifestyle modifications.5-10% reduction in body weight improves insulin sensitivity, lipid profiles, endothelial function, reduces thrombosis and inflammatory markers.There is a 3-fold increase in the odds that a patient will attempt weight loss if it is recommended by a trusted health care professional.N Engl J Med Feb 7;346(6):Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.SourceDiabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852, USA.AbstractBACKGROUND:Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.METHODS:We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups.RESULTS:The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin.CONCLUSIONS:Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.Ann Intern Med Apr 19;142(8):611-9.The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.Diabetes Prevention Program Coordinating Center, The Biostatistics Center, George Washington University, Rockville, Maryland 20852, USA.The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance.OBJECTIVE:To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution.DESIGN:Randomized, controlled clinical trial.SETTING:Research and community-based centers.PARTICIPANTS:Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level >or=5.3 mmol/L [>or=95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo.INTERVENTIONS:Metformin, 850 mg twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week.MEASUREMENTS:The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III.Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51%, 45%, and 34% in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group.LIMITATIONS:The study involved a volunteer group with impaired glucose tolerance, which limits generalizability.The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.
60 Andrea M Girman, MD, MPH PAFP 9 March 2012 The Continuum of PreD: Guiding Diagnosis & Treatment of Progression to DiabetesAndrea M Girman, MD, MPHPAFP9 March 2012
Your consent to our cookies if you continue to use this website.